Carteyva, JW Therapeutics, lymphoma, refractory follicular lymphoma, RELIANCE study, relmacabtagene autoleucel
JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma
SHANGHAI, CHINA, October 10, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy products, announced that the Na..
Genentech, Lunsumio, mosunetuzumab-axgb, refractory follicular lymphoma
Mosunetuzumab-axgb is granted accelerated approval for relapsed or refractory follicular lymphoma
Jan 2023: Mosunetuzumab-axgb (Lunsumio, Genentech, Inc.), a bispecific CD20-directed CD3 T-cell engager for adult patients with relapsed or refractory follicular lymphoma (FL) following two or more rounds of systemic therapy, rece..
axicabtagene ciloleucel, CAR - T Cell therapy, CD19, follicular lymphoma, Kite Pharma, refractory follicular lymphoma, relapsed follicular lymphoma, Yescarta
The FDA has granted axicabtagene ciloleucel expedited approval for relapsed or refractory follicular lymphoma.
August 2021: The FDA has given axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) expedited approval for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. A sing..